Deciphera Pharmaceuticals Inc Stock News

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has been assigned a consensus recommendation of Hold from the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month []

The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.

(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Commission has approved Qinlock or ripretinib in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The approval is

QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study - Deciphera Pharmaceuticals, Inc. (NAS

The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prio

Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagshi

Equities analysts expect Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) to report $23.44 million in sales for the current quarter, according to Zacks. Seven analysts have made estimates for Deciphera Pharmaceuticals earnings. The lowest sales estimate is $19.46 million and the highest is $27.11 million. Deciphera Pharmaceuticals reported sales of $19.49 million in the same quarter last year, []

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip. The post Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip.

Today, investors in Deciphera Pharmaceuticals and DCPH stock have seen tremendous selling pressure take this stock to all-time lows. The post DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plungin

Shares of Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) tanked 75% on Friday morning after the U.S. firm said its INTRIGUE Phase III Clinical Study failed to meet the primary endpoint. The sharp declin

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in patients with gastrointestinal stromal t

Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2021 Results - Earnings Call Transcript

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.20% and -2.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f